Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PPM1B | O75688 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211421 | 0.87 | NPC1 (0.52) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL12487985 | 0.82 | PPM1B (0.52) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL7195220 | 0.80 | NPC1 (0.52) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL7198226 | 0.80 | NPC1 (0.52) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL17041424 | 0.80 | NPC1 (0.49) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL7195218 | 0.80 | NPC1 (0.52) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL9512301 | 0.78 | TDP1 (0.51) | — | |
| SCHEMBL12487620 | 0.78 | NPC1 (0.53) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL12487615 | 0.78 | NPC1 (0.53) | NPC1PPM1BMEN1CYP1A2CYP2C19 | |
| SCHEMBL20879382 | 0.78 | NPC1 (0.53) | NPC1PPM1BMEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288213-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL|ACETIC ACID DERIVATIVES | KANEKA CORP (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060246557-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7094594-B2 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20050080277-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1288213-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246557-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | HAAO, APEH, HPD | NPC1 4613/4885PPM1B 2602/4885MEN1 1586/4885 |
| US-20050080277-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | HAAO, APEH, HPD | NPC1 4563/4885PPM1B 2805/4885MEN1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.